National Hospital Organization Kyushu Cancer Center

Fukuoka, Japan
どくりつぎょうせいほうじんこくりつびょういんきこう きゅうしゅうがんセンター

About National Hospital Organization Kyushu Cancer Center


独立行政法人国立病院機構九州がんセンターは、福岡県福岡市南区野多目にある医療機関。独立行政法人国立病院機構が運営する病院である。がん専門病院であり、がん政策医療ネットワークの基幹医療施設である。福岡県の都道府県がん診療連携拠点病院に指定されている。
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Pfizer
20
Hoffmann-La Roche
14
Daiichi Sankyo, Inc.
9
Daiichi Sankyo Co., Ltd.
5
Incyte Corporation
5
Eli Lilly and Company
3
BeiGene
2
Chugai Pharmaceutical
2
Incyte Biosciences Japan GK
2
Puma Biotechnology, Inc.
2
AnHeart Therapeutics Inc.
1
Total Rows: 23

Clinical Trials at National Hospital Organization Kyushu Cancer Center


During the past decade, National Hospital Organization Kyushu Cancer Center conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 32 clinical trials were completed, i.e. on average, 55.2% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 18 clinical trials were completed. i.e. 94.7% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years33771010161633771010221144553311883344Started TrialsCompleted Trails2015201620172018201920202021202205101520
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
2009-02-04
2018-06-03
Completed
233
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
2007-12-01
2015-06-01
Completed
63
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
2009-07-30
2013-06-27
Completed
81
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
2009-07-09
2019-10-04
Completed
2,840
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
2011-03-22
2023-04-28
Active, not recruiting
44
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
2011-01-13
2016-11-30
Completed
343
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
2012-08-02
2017-01-04
Completed
326
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
2012-06-17
2016-05-23
Completed
800

Rows per page:

1–77 of 77

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "National Hospital Organization Kyushu Cancer Center" #1 sponsor was "Pfizer" with 20 trials, followed by "Hoffmann-La Roche" with 14 trials sponsored, "Daiichi Sankyo, Inc." with 9 trials sponsored, "Daiichi Sankyo Co., Ltd." with 5 trials sponsored and "Incyte Corporation" with 5 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 23 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "National Hospital Organization Kyushu Cancer Center" #1 collaborator was "AstraZeneca" with 10 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 5 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator and "Japan Lung Cancer Society" with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 24 trials.
Created with Highcharts 11.1.0Top Leading SponsorsPfizer: 20Pfizer: 20Hoffmann-La Roche: 14Hoffmann-La Roche: 14Daiichi Sankyo, Inc.: 9Daiichi Sankyo, Inc.: 9Daiichi Sankyo Co., Ltd.: 5Daiichi Sankyo Co., Ltd.: 5Incyte Corporation: 5Incyte Corporation: 5Eli Lilly and Company: 3Eli Lilly and Company: 3BeiGene: 2BeiGene: 2Chugai Pharmaceutical: 2Chugai Pharmaceutical: 2Incyte Biosciences Japan GK: 2Incyte Biosciences Japan GK: 2Puma Biotechnology, Inc.: 2Puma Biotechnology, Inc.: 2

Created with Highcharts 11.1.0Top CollaboratorsAstraZeneca: 10AstraZeneca: 10Daiichi Sankyo Co., Ltd.: 5Daiichi Sankyo Co., Ltd.: 5Eli Lilly and Company: 2Eli Lilly and Company: 2European Network ofGynaecologicalOncological Trial Groups(ENGOT): 2European Network ofGynaecologicalOncological Trial Groups(ENGOT): 2Japan Lung Cancer Society: 2Japan Lung Cancer Society: 2Merck KGaA,Darmstadt, Germany: 2Merck KGaA,Darmstadt, Germany: 2Merck Sharp & Dohme LLC: 2Merck Sharp & Dohme LLC: 2Ono Pharmaceutical Co. Ltd: 2Ono Pharmaceutical Co. Ltd: 2UCB Pharma: 2UCB Pharma: 2ADIR, a Servier Groupcompany: 1ADIR, a Servier Groupcompany: 1

Clinical Trials Conditions at National Hospital Organization Kyushu Cancer Center


According to Clinical.Site data, the most researched conditions in "National Hospital Organization Kyushu Cancer Center" are "Breast Cancer" (9 trials), "Breast Neoplasms" (5 trials), "Non-Small Cell Lung Cancer" (5 trials), "Lymphoma" (3 trials) and "Non Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "National Hospital Organization Kyushu Cancer Center" in a lesser frequency.

Clinical Trials Intervention Types at National Hospital Organization Kyushu Cancer Center


Most popular intervention types in "National Hospital Organization Kyushu Cancer Center" are "Drug" (74 trials), "Biological" (2 trials), "Other" (2 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (13 trials), "Gemcitabine" (8 trials), "Carboplatin" (7 trials), "Paclitaxel" (7 trials) and "Cisplatin" (6 trials). Other intervention names were less common.

Clinical Trials Genders at National Hospital Organization Kyushu Cancer Center


The vast majority of trials in "National Hospital Organization Kyushu Cancer Center" are 69 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Clinical Trials Status at National Hospital Organization Kyushu Cancer Center


Currently, there are NaN active trials in "National Hospital Organization Kyushu Cancer Center". undefined are not yet recruiting, 13 are recruiting, 30 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in National Hospital Organization Kyushu Cancer Center, undefined suspended trials, and 4 terminated clinical trials to date.
Out of the total trials that were conducted in National Hospital Organization Kyushu Cancer Center, 12 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 37Phase 3: 37Phase 2: 28Phase 2: 28Phase 1: 12Phase 1: 12

Created with Highcharts 11.1.0Trials StatusActive, not recruiting: 30Active, not recruiting: 30Completed: 30Completed: 30Recruiting: 13Recruiting: 13Terminated: 4Terminated: 4